(Q37790702)

23 August 2017

title

Product development issues for PEGylated proteins (English)

1 reference

23 August 2017

Robert W Payne

1

1 reference

23 August 2017

Brian M Murphy

series ordinal

2

1 reference

23 August 2017

Mark Cornell Manning

series ordinal

3

1 reference

23 August 2017

publication date

21 September 2010

1 reference

Pharmaceutical Development and Technology

23 August 2017

published in

1 reference

23 August 2017

volume

16

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

423-440

1 reference

Modificomics: posttranslational modifications beyond protein phosphorylation and glycosylation

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Effects of glycosylation on the stability of protein pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

21 January 2018

Emerging PEGylated drugs

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Pharmacokinetic consequences of pegylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

PEGylated antibodies and antibody fragments for improved therapy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Pegylation: a novel process for modifying pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

PEGylation of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

The impact of PEGylation on biological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

PEGylation, successful approach to drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Peptide and protein PEGylation: a review of problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Advances in PEGylation of important biotech molecules: delivery aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

PEG conjugates in clinical development or use as anticancer agents: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Anti-cancer PEG-enzymes: 30 years old, but still a current approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Delivery of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Degradation of O6-benzylguanine in aqueous polyethylene glycol 400 (PEG 400) solutions: concerns with formaldehyde in PEG 400.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Influence of formaldehyde impurity in polysorbate 80 and PEG-300 on the stability of a parenteral formulation of BMS-204352: identification and control of the degradation product

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Use of the antioxidant BHT in asymmetric membrane tablet coatings to stabilize the core to the acid catalyzed peroxide oxidation of a thioether drug

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Microbial degradation of polyethers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

A new ether bond-splitting enzyme found in Gram-positive polyethylene glycol 6000-utilizing bacterium, Pseudonocardia sp. strain K1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Autoxidation of Polysorbates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Peroxide formation in polysorbate 80 and protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Chemistry for peptide and protein PEGylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Polypeptide-polymer bioconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Surface modification of proteins. Activation of monomethoxy-polyethylene glycols by phenylchloroformates and modification of ribonuclease and superoxide dismutase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Polyethylene glycol conjugation of recombinant methioninase for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Biochemical and biopharmaceutical properties of PEGylated uricase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Site-specific pegylation of G-CSF by reversible denaturation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Preparation of characterization of poly(ethylene glycol) vinyl sulfone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Protected thiol-polyethylene glycol: a new activated polymer for reversible protein modification

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Conjugation of multiple copies of polyethylene glycol to hemoglobin facilitated through thiolation: influence on hemoglobin structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Enhanced molecular volume of conservatively pegylated Hb: (SP-PEG5K)6-HbA is non-hypertensive

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

The preparation and properties of novel reversible polymer-protein conjugates. 2-omega-Methoxypolyethylene (5000) glycoxymethylene-3-methylmaleyl conjugates of plasminogen activators

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Effective drug delivery by PEGylated drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Linear and branched bicin linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Reversible pegylation of insulin facilitates its prolonged action in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Releasable PEGylation of proteins with customized linkers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Site-specific PEGylation of native disulfide bonds in therapeutic proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Disulfide bridge based PEGylation of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

In vivo incorporation of an alkyne into proteins in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Increased activity and stability of poly(ethylene glycol)-modified trypsin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Site-specific modification of interleukin-2 by the combined use of genetic engineering techniques and transglutaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Enzymatic procedure for site-specific pegylation of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Site-directed enzymatic PEGylation of the human granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Pegaspargase: a review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

New PEGs for peptide and protein modification, suitable for identification of the PEGylation site

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Enzymatic activity of chymotrypsin and its poly(ethylene glycol) conjugates toward low and high molecular weight substrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Characterization and stability of N-terminally PEGylated rhG-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Biochemical and biophysical characterization of lysozyme modified by PEGylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Improved biological and transcriptional activity of monopegylated interferon-α-2a isomers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Long-acting growth hormones produced by conjugation with polyethylene glycol.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Induced plasma expander-like properties as a function of PEG-chains on extension arm facilitated PEGylation of albumin: "mushroom to brush-like" conformational transition of the PEG-albumin conjugate.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Effect of molecular size of PEGylated recombinant human epidermal growth factor on the biological activity and stability in rat wound tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein conjugated with high molecular weight polyethylene glycol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

PEGylation of growth hormone-releasing hormone (GRF) analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Mono-N-terminal poly(ethylene glycol)-protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

A general method for highly selective cross-linking of unprotected polypeptides via pH-controlled modification of N-terminal alpha-amino groups

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Use of ion-exchange chromatography and hydrophobic interaction chromatography in the preparation and recovery of polyethylene glycol-linked proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Design and synthesis of N-maleimido-functionalized hydrophilic polymers via copper-mediated living radical polymerization: a suitable alternative to PEGylation chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: synthesis, characterization and cellular uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Autoxidation of the site-specifically PEGylated hemoglobins: role of the PEG chains and the sites of PEGylation in the autoxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Effects of PEG conjugation on insulin properties

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Preliminary characterization of bovine beta-lactoglobulin after its conjugation to polyethylene glycol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Protein-solute interactions affect the outcome of ultrafiltration/diafiltration operations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Designing PEGylated therapeutic molecules: advantages in ADMET properties

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Size-exclusion reaction chromatography (SERC): a new technique for protein PEGylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Online size-exclusion high-performance liquid chromatography light scattering and differential refractometry methods to determine degree of polymer conjugation to proteins and protein-protein or protein-ligand association states.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Preformulation development of recombinant pegylated staphylokinase SY161 using statistical design

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Reproducible preparation and effective separation of PEGylated recombinant human granulocyte colony-stimulating factor with novel "PEG-pellet" PEGylation mode and ion-exchange chromatography.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Separation of positional isomers of mono-poly(ethylene glycol)-modified octreotides by reversed-phase high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Optimization of octreotide PEGylation by monitoring with fast reversed-phase high-performance liquid chromatography.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Formulation of Neulasta (pegfilgrastim).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Rapid online proteolytic mapping of PEGylated rhGH for identity confirmation, quantitation of methionine oxidation and quantitation of UnPEGylated N-terminus using HPLC with UV detection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Native PAGE eliminates the problem of PEG-SDS interaction in SDS-PAGE and provides an alternative to HPLC in characterization of protein PEGylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Detection of PEGylated proteins in polyacrylamide gels by reverse staining with zinc and imidazole salts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Comparison of results of various methods used to determine the extent of modification of methoxy polyethylene glycol 5000-modified bovine cupri-zinc superoxide dismutase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Quantitatively investigating monomethoxypolyethylene glycol modification of protein by capillary electrophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Capillary electrophoretic characterization of PEGylated human parathyroid hormone with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Capillary electrophoretic separation of high-molecular-weight poly(ethylene glycol)-modified proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Bioanalytical applications of capillary electrophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Capillary electrophoresis in bioanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Solution structure of poly(ethylene) glycol-conjugated hemoglobin revealed by small-angle X-ray scattering: implications for a new oxygen therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Effect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Thermostability of native and pegylated Myceliophthora thermophila laccase in aqueous and mixed solvents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

21 January 2018

Tissue sulfhydryl groups

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Poly(ethylene glycol)-conjugated human serum albumin including iron porphyrins: surface modification improves the O2-transporting ability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Conformational stability of lyophilized PEGylated proteins in a phase-separating system.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Stabilization of alpha-chymotrypsin upon PEGylation correlates with reduced structural dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Influence of the chemistry of conjugation of poly(ethylene glycol) to Hb on the oxygen-binding and solution properties of the PEG-Hb conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Tailored PEG for rh-G-CSF analogue site-specific conjugation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Monitoring manufacturing process yields, purity and stability of structural variants of PEGylated staphylokinase mutant SY161 by quantitative reverse-phase chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Rational design of stable lyophilized protein formulations: some practical advice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Characterization of a monoPEG20000-Endostar.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Characterisation and physical stability of PEGylated glucagon

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1-29).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Pegvisomant in the treatment of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

In vitro release study of mono-PEGylated growth hormone-releasing peptide-6 from PLGA microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Solid phase pegylation of hemoglobin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Enhancing nitrite reductase activity of modified hemoglobin: bis-tetramers and their PEGylated derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Chemical modification of recombinant human keratinocyte growth factor 2 with polyethylene glycol improves biostability and reduces animal immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Clinical development of PEGylated recombinant staphylokinase (PEG–Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

PEG-uricase in the management of treatment-resistant gout and hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

PEG-proteins: Reaction engineering and separation issues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

Therapeutic antibody fragments with prolonged in vivo half-lives

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10837450.2010.513990

10.3109/10837450.2010.513990

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference